Thermo Fisher Scientific Announces Next-Generation Sequencing Oncomine Focus Assay for Oncology Research

Translational and clinical research laboratories now have access to a multi-biomarker, next-generation sequencing (NGS) panel that includes 52 solid tumor genes associated with current oncology drugs and published evidence. The Oncomine Focus Assay by Thermo Fisher Scientific (NYSE: TMO) is being featured at the American Association for Cancer Research conference taking place April 18-22 at the Pennsylvania Convention Center in Philadelphia.


Combined with a simplified workflow and favorable economics for detection of relevant genes, this new next-generation sequencing assay further expands the capability of translational and clinical research laboratories, allowing them to advance precision oncology within their own communities and improve the future of cancer care.